What is Gelesis Holdings Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Gelesis Holdings's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.13.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Gelesis Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.
The historical rank and industry rank for Gelesis Holdings's Cash-to-Debt or its related term are showing as below:
GLSHQ'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.43 Max: 0.9
Current: 0.13
During the past 2 years, Gelesis Holdings's highest Cash to Debt Ratio was 0.90. The lowest was 0.05. And the median was 0.43.
Gelesis Holdings Cash-to-Debt Historical Data
The historical data trend for Gelesis Holdings's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Gelesis Holdings Cash-to-Debt Chart
|
Gelesis Holdings Annual Data
|
|
Trend |
Dec21 |
Dec22 |
| Cash-to-Debt |
|
0.43 |
0.12 |
|
Gelesis Holdings Quarterly Data
|
|
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
0.73 |
0.43 |
0.12 |
0.05 |
0.13 |
Competitive Comparison of Gelesis Holdings's Cash-to-Debt
For the Biotechnology subindustry, Gelesis Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelesis Holdings's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Gelesis Holdings's Cash-to-Debt falls into.
Gelesis Holdings Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Gelesis Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
Gelesis Holdings's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gelesis Holdings (Gelesis Holdings) Business Description
Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
| Raju S Kucherlapati |
director |
77 LOUIS PASTEUR AVENUE, BOSTON MA 02115 |
| Bomsmaster Llc |
10 percent owner |
195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510 |
| Paul R. Fonteyne |
director |
C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116 |
| Hpso Spv Ltd |
10 percent owner |
SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA |
| Alessandro Sannino |
officer: Lead Project Scientist |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Dominic Perks |
director |
GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116 |
| David A. Pass |
officer: Chief Op. & Comm. Officer |
GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116 |
| Elaine Chiquette |
officer: Chief Scientific Officer |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Jane Wildman |
director |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Harry L. Leider |
officer: Chief Medical Officer |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Clayton Christopher |
director |
2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704 |
| Health Plc Puretech |
10 percent owner |
6 TIDE STREET, SUITE 400, BOSTON MA 02210 |
| Ssd2, Llc |
10 percent owner |
142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511 |
| Yishai Zohar |
director, officer: President & CEO |
C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116 |
| Elon Boms |
10 percent owner |
C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510 |
Gelesis Holdings (Gelesis Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSHQ has been successfully added to your